These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2004-001449-13 Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy. 2006-05-31 due-trials
Not reported 2004-001450-84 Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study 2006-04-19 due-trials
Not reported 2004-001452-36 Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study 2006-04-19 due-trials
Not reported 2005-000140-85 Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomi... 2007-03-20 due-trials
Not reported 2005-000142-37 Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin... 2007-05-10 due-trials
Not reported 2005-000144-87 Long-term efficacy and safety of subcutaneous administration of XM01 in chronic renal failure patients and comparison of once-weekly with three-times weekly administration of XM01 - A multinational, m... 2008-01-21 due-trials
Not reported 2007-005349-39 Dose-finding of a fixed dose XM22 in patients with breast cancer receiving 4 cycles of chemotherapy versus 6 mg Neulasta® 2009-12-10 due-trials
Completed, but no date, and reported results 2009-015999-10 Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study bad-data
Reported results 2009-016000-22 Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study 2011-12-19 due-trials
Not reported 2009-017674-20 Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoing assisted reproductive technologies. A multi-national, multi-centre, randomised, controlled, assessor-blind, parallel ... 2011-09-18 due-trials